News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fresenius Kabi AG Announces Availability of Acetylcysteine Solution, USP, 20%


10/1/2012 10:33:57 AM

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi USA, LLC today announced the launch of Acetylcysteine Solution, USP, 20% 30 mL vial for inhalation (mucolytic agent) or oral administration (acetaminophen antidote). For inhalation, it is used as adjuvant therapy for patients with certain lung diseases including chronic and acute bronchopulmonary disease. Inhalation therapy reduces the viscosity of mucus, thinning mucus secretions. When administered orally, it is used to prevent or lessen hepatic injury following acetaminophen overdose.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES